Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • regulatory issues

    EU flag

    EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy

    An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019

    - PMLiVE

    FDA grants interchangeable designation to Celltrion’s Humira biosimilar Yuflyma

    The drug is approved for inflammatory conditions such as Crohn's disease and plaque psoriasis

    EU flag

    EC approves Biocon’s Stelara biosimilar Yesintek for inflammatory diseases

    The drug has been approved to treat plaque psoriasis, psoriatic arthritis and Crohn’s disease

    EU flag

    EC approves Celltrion’s Stelara biosimilar SteQeyma for inflammatory diseases

    The drug has been authorised for use in gastroenterology, dermatology and rheumatology indications

    - PMLiVE

    Sandoz separates from Novartis as an independent spin-off company

    The split allows Sandoz to strengthen its position in generics and biosimilars

    - PMLiVE

    Sandoz launches high-concentration biosimilar of AbbVie’s Humira in the US

    Hyrimoz HCF is approved to treat indications including rheumatoid arthritis and Crohn’s disease

    - PMLiVE

    Sandoz and Just-Evotec Biologics announce multi-year biosimilar partnership

    The Novartis unit will aim to expand its current pipeline of biosimilars to about 24 candidates

    - PMLiVE

    Sandoz launches ‘Act4Biosimilars’ initiative to address global health inequalities

    The initiative wants to increase the global use of biosimilars by at least 30% by 2030

    - PMLiVE

    Biosimilars boosted by FDA’s landmark ruling for Boehringer’s Cyltezo

    The FDA has approved Boehringer’s Cyltezo (adalimumab-adbm) as ‘interchangeable’ with Humira (adalimumab) in a landmark ruling

    - PMLiVE

    Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars

    Competition created by biosimilars has delivered $9.8bn in savings over five years and could reduce patients’ out-of-pocket costs by $238m

    - PMLiVE

    Piloting a route to the biosimilars opportunities in Europe

    Investigating the EU regulatory hurdles that life sciences companies face as they seek to improve patient access to biosimilar therapy

    Roche Basel Switzerland

    Roche’s diagnostic business sales offer a bright spot in Q4

    Company's pharmaceutical division sales slipped due to biosimilar competition

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links